Lupin partners with Amman Pharmaceuticals Industries

10 Nov 2023 Evaluate

Lupin has partnered with Amman Pharmaceuticals Industries (Amman Pharma), a leading pharmaceutical manufacturer with operations across the MENA region and other global markets, for exclusive marketing and commercialization of Ranibizumab, a biosimilar of Lucentis, in the Middle East region, including select territories of Jordan, Saudi Arabia, UAE, Iraq, Lebanon and other GCC countries. Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the Middle East and North Africa (MENA) region.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

1608.50 3.10 (0.19%)
13-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1506.90
Dr. Reddys Lab 6087.65
Cipla 1543.45
Zydus Lifesciences 1093.00
Lupin 1608.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.